Discounted Cash Flow
Innate Pharma S.A. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $44.0m | $-48.0m | $-69.5m | -109.0% | $-0.89 |
| 2018 | $94.0m (113.4%) | $2.7m (105.7%) | $2.7m (103.9%) | 2.9% (102.7%) | $0.05 (105.6%) |
| 2019 | $85.8m (-8.7%) | $-20.8m (-863.8%) | $6.2m (128.4%) | -24.2% (-936.2%) | $-0.31 (-720.0%) |
| 2020 | $70.5m (-17.9%) | $-64.0m (-208.2%) | $-103.4m (-1765.6%) | -90.8% (-275.4%) | $-0.81 (-161.3%) |
| 2021 | $24.7m (-64.9%) | $-45.5m (28.9%) | $-106.7m (-3.2%) | -184.1% (-102.7%) | $-0.66 (18.5%) |
| 2022 | $57.7m (133.5%) | $-58.0m (-27.5%) | $-71.6m (32.9%) | -100.5% (45.4%) | $-0.73 (-10.6%) |
| 2023 | $61.6m (6.9%) | $-7.6m (86.9%) | $-7.6m (89.4%) | -12.3% (87.8%) | $-0.09 (87.7%) |
| 2024 | $20.1m (-67.4%) | $-49.5m (-553.5%) | $-21.2m (-180.0%) | -245.9% (-1902.1%) | $-0.61 (-577.8%) |
| 2025 | $9.0m (-55.2%) | $-49.2m (0.6%) | $-65.4m (-208.6%) | -546.1% (-122.1%) | $-0.55 (9.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.